A Phase Ib Study of HS-10352 Plus Fulvestrant in Patients With Advanced Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: HS-10352 combined with fulvestrant (Stage 1)|DRUG: HS-10352 combined with fulvestrant (Stage 2)
Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.